CEO Nadav Kidron spoke to CNBC's Capital Connection about Oramed's new venture, Oravax Medical and bringing an oral Covid-19 vaccine to market. He spoke about how an oral vaccine will help cut down logistical challenges and waste and how it will be an “essential product” [...]
CEO Nadav Kidron talks to Nicole Petallides of TD Ameritrade's The Watch about $ORMP's Covid-19 oral vaccine developments and progress on oral insulin for diabetes. Watch here.
“This has the potential to improve lives of hundreds of millions of diabetics worldwide,” Oramed CEO Nadav Kidron told The Times of Israel. “And by improving treatment it can reduce complications and, in turn, reduce the cost of treating diabetics.” Read more here.
CEO Nadav Kidron discusses oral insulin and Phase 3 trials on i24News. Watch the interview here.
Webinar discussing oral insulin and the path to Phase 3 trials: The Journey of Oral Insulin: The Oramed Story (Part 1) ft. Nadav Kidron The Journey of Oral Insulin: The Oramed Story (Part 2) ft. Prof. Avram Hershko and Dr Miriam Kidron
CEO Nadav Kidron spoke to SABC News' First Take about the potential of oral insulin. SABC writes: "There is good news beckoning on the horizon. Oramed Pharmaceuticals a biotechnology company based in the United States and Israel is developing an oral drug delivery system aptly [...]
Medwire News reports from the EASD: Oramed's "oral insulin ORMD-0801 warrants further investigation as a treatment option for patients with inadequately controlled type 2 diabetes, indicate findings from a phase 2b trial presented at the virtual 56th EASD Annual Meeting." Read more: Novel oral insulin [...]
Forbes story about Oramed and the latest results from Phase 2b trials - Read here: Diabetic Patients Get Ready: An Oral Insulin Capsule That May Soon Be On The Market
CEO Nadav Kidron speaks with i24 News about the potential of oral insulin. Read and Watch here.
Nadav Kidron, CEO at Oramed Pharmaceuticals, spoke to Bloomberg Business Week radio about the development of an insulin pill for the treatment of Type 2 diabetes. Listen to the segment here (begins at 13:33).